share_log

Panbela Therapeutics | 8-K: Current report

SEC announcement ·  Mar 26 16:16
Summary by Moomoo AI
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more